

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN SELECTIVE THYROID
HORMONE RECEPTOR-BETA AGONISTS,
PROCESSES FOR MANUFACTURING OR
RELATING TO SAME, AND PRODUCTS
CONTAINING SAME**

Investigation No. 337-TA-1352

**NOTICE OF A COMMISSION DECISION TO EXTEND THE DEADLINE
FOR DETERMINING WHETHER TO REVIEW A FINAL INITIAL
DETERMINATION FINDING A VIOLATION OF SECTION 337
AND TO EXTEND THE TARGET DATE**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (the “Commission”) has determined to extend the deadline for determining whether to review a final initial determination (“FID”) of the presiding Chief Administrative Law Judge (“Chief ALJ”) finding a violation of section 337 until January 31, 2025, and to extend the target date for completion of the investigation until April 3, 2025.

FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708-4716. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket system (“EDIS”) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on February 9, 2023, based on a complaint, as supplemented, filed on behalf of Viking Therapeutics, Inc. of San Diego, California. *See* 88 FR 8455-57 (Feb. 9, 2023). The complaint alleges a violation of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by way of the importation into the United States or in the sale of certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure a domestic industry or prevent the establishment of a domestic industry. *Id.* at 8455-56. The notice of investigation named the following as respondents: Ascleptis Pharma

Inc. of Hangzhou, Zhejiang Province, China; Ascleto Pharmaceuticals Co. Ltd. of Shaoxing, Zhejiang Province, China; Ascleto Bioscience Co., Ltd. of Hangzhou, Zhejiang Province, China; Gannex Pharma Co., Ltd. of Shanghai, China; and Jinzi Jason Wu of Seattle, Washington. *Id.* at 8456. The Office of Unfair Import Investigation is also participating in this investigation. *Id.*

On September 22, 2023, the Commission granted a motion to intervene filed by Foster, Murphy, Altman & Nickel, PC. *See* Order No. 37 (Aug. 28, 2023), *unreviewed by* Comm'n Notice (Sept. 22, 2023).

On October 3, 2024, the Chief ALJ issued the FID finding a violation of section 337. Petitions for review are currently due on November 8, 2024, and responses thereto are due on November 27, 2024.

The Commission has determined to extend the deadline for determining whether to review the FID until January 31, 2025, and to extend the target date for completion of the investigation until April 3, 2025.

The Commission's vote for this determination took place on December 2, 2024.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.



Lisa R. Barton
Secretary to the Commission

Issued: December 2, 2024